Methods for increasing sepiapterin plasma exposure
AssigneePTC Therapeutics MP, Inc.
InventorsNeil SMITH, Jonathan REIS
Life of this patent
Estimating the term…
Abstract
The present invention features compositions including sepiapterin, or a pharmaceutically acceptable salt thereof, and methods for the treatment of BH4-related disorders. In some embodiments, these compositions and methods result in an increase in plasma. CSF, and/or brain exposure of sepiapterin.
Claims13
A method of treating a BH4-related disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of sepiapterin, or a pharmaceutically acceptable salt thereof, without food.
A method of increasing the rate of absorption and/or decreasing peripheral conversion into BH4 of an oral dosage form of sepiapterin, or a pharmaceutically acceptable salt thereof, as measured by the concentration of sepiapterin attained in the plasma over time in a subject in need thereof, the method comprising administering to the subject an effective amount of sepiapterin, or a pharmaceutically acceptable salt thereof, without food.
A method of increasing the level of homovanillic acid and/or 5-hydroxyindoleacetic acid in a subject, the method comprising administering an effective amount of sepiapterin, or a pharmaceutically acceptable salt thereof, without food.
Dependencies are inferred from the claim text.